Hainan Shuangcheng Pharmaceuticals Co., Ltd.

符号: 002693.SZ

SHZ

5.69

CNY

今天的市场价格

-39.5632
市盈率
2.2749
PEG比率
2.36B
MRK市值
0.00%
DIV收益率

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) 财务报表

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ). 的默认数据。公司收入显示 212.148 M 的平均值，即 0.079 % 增长率。整个期间的平均毛利润为 144.08 M，即 0.085 %. 平均毛利率为 0.676 %. 公司去年的净收入增长率为 4.972 %，等于 -2.305 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Hainan Shuangcheng Pharmaceuticals Co., Ltd. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.118. 在流动资产领域，002693.SZ 的报告货币为135.236. 这些资产中的很大一部分，即 31.904 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.781%. 公司的长期投资虽然不是其重点，但以报告货币计算的10（如果有的话）为10。这表明与上一报告期相比，13.709% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 135. 这一数字表明，-0.293% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 471.486. 这方面的年同比变化率为 -0.082%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为16.359，存货估值为 74.31，商誉估值为 0（如有. 无形资产总额（如果有）按 171.78 估值. 应付账款和短期债务分别为 17.14 和 10.05. 债务总额为145.05，债务净额为 141.66. 其他流动负债为 2.04，加上总负债 285.6. 最后，如果存在推荐股票，则其估值为 34.43.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010
balance-sheet.row.cash-and-short-term-investments	291.41	31.9	146	77	100	95.5	68.1	31.7	25	246.2	85.4	346.8	446.8	33.6	149.8	9.9
balance-sheet.row.short-term-investments	223.27	28.5	133.8	55.4	94.3	52.8	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	97.01	16.4	41	33.1	44.6	82.2	69.2	244.7	84.2	201.1	102.7	65.8	36.1	50.4	23.9	16.4
balance-sheet.row.inventory	306.61	74.3	65.4	55.2	52.8	47.6	86.3	119.9	34.2	28.3	53.1	30.6	23.5	12.2	10.4	9.8
balance-sheet.row.other-current-assets	0.25	0.2	0	0.1	0	0	148.6	161.7	8	3.4	380	220	161	-0.8	-2.5	-4.3
balance-sheet.row.total-current-assets	721.6	135.2	252.4	165.4	197.5	225.4	372.1	557.9	151.4	479	621.2	663.2	667.4	95.5	181.6	31.8
balance-sheet.row.property-plant-equipment-net	1823.92	457.6	471.8	504.7	541	601.1	637.8	679.5	658.9	443.2	264.1	213.3	182.1	133.8	54.2	53.4
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	688.05	171.8	164.9	156.9	134.4	115.2	96.5	101.2	105.9	134.2	48.2	33.5	33.3	18.2	16.4	12.1
balance-sheet.row.goodwill-and-intangible-assets	688.05	171.8	164.9	156.9	134.4	115.2	96.5	101.2	105.9	134.2	48.2	33.5	33.3	18.2	16.4	12.1
balance-sheet.row.long-term-investments	44.81	10	8.8	17.3	25.9	3.1	3.3	3.7	215.1	412.9	0	0	0	0	0	0
balance-sheet.row.tax-assets	4.76	1.5	1	1	0.7	0.7	1.5	1.2	3	5.9	4	2.6	2.4	0.3	0.2	0.2
balance-sheet.row.other-non-current-assets	83.17	27.1	12.2	9.1	8.3	5.4	9	37.3	246.4	487.9	6	4.4	1.5	0.2	0.2	0.3
balance-sheet.row.total-non-current-assets	2644.71	668	658.6	689.1	710.2	725.6	748.1	819.2	1014.1	1071.1	322.3	253.9	219.3	152.6	71.1	66
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	3366.32	803.2	911	854.6	907.7	951	1120.2	1377.1	1165.5	1550.2	943.5	917	886.7	248.1	252.7	97.9
balance-sheet.row.account-payables	61.58	17.1	15.5	17.2	15.4	9.9	11.8	80.5	28.5	13.2	8.9	10.7	10.7	7.1	3.9	7.5
balance-sheet.row.short-term-debt	388.3	10.1	205.3	0.3	55.7	0.3	0	0	190	345	0	0	0	0	0	0
balance-sheet.row.tax-payables	13.4	3.7	12.8	7.2	6.3	10.1	5.3	8.8	4.5	11.9	7.2	8.3	6.7	4	4.5	4.5
balance-sheet.row.long-term-debt-total	290.02	135	0	167	167	167	306	367	297	145	0	0	0	0	0	0
Deferred Revenue Non Current	31.26	8	7.6	8.9	10.3	10.5	31.1	32.8	33.8	32	26.6	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	11.26	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	9.06	2	73.6	1.8	1.5	13.3	95	120.1	36.6	86.5	13.8	18.3	14.3	10.7	89.3	10.6
balance-sheet.row.total-non-current-liabilities	332.55	145.7	10.7	179.4	180	179.1	343.7	414.8	357.3	177.9	27.3	17.4	15.9	2.1	1.8	1.8
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1177.06	285.6	330.1	287.8	309.4	272.7	450.6	615.4	612.4	622.6	50	46.4	40.8	19.8	94.9	19.9
balance-sheet.row.preferred-stock	68.85	34.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	1666.33	416.7	414.7	412	405	405	405	405	405	419.2	270	180	120	90	90	5
balance-sheet.row.retained-earnings	-1287.93	-347	-296.2	-305.2	-284.6	-231.3	-256	-186.5	-192.8	195.6	174.1	157.1	138.9	77.7	14.3	65.8
balance-sheet.row.accumulated-other-comprehensive-income-loss	501.27	-0.4	87.2	82.2	86	86	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	1044.52	367.6	307.9	292.9	286.5	286.5	373	372.9	340.9	312.8	449.4	533.6	586.9	60.5	53.5	7.2
balance-sheet.row.total-stockholders-equity	1993.04	471.5	513.5	481.8	492.9	546.3	522.1	591.4	553.1	927.6	893.6	870.6	845.8	228.2	157.8	77.9
balance-sheet.row.total-liabilities-and-stockholders-equity	3366.32	803.2	911	854.6	907.7	951	1120.2	1377.1	1165.5	1550.2	943.5	917	886.7	248.1	252.7	97.9
balance-sheet.row.minority-interest	196.22	46.2	67.4	84.9	105.4	132	147.6	170.3	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	2189.26	517.6	580.9	566.8	598.3	678.3	669.7	761.7	553.1	927.6	893.6	870.6	845.8	228.2	157.8	77.9
balance-sheet.row.total-liabilities-and-total-equity	3366.32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	206.63	10	133.8	55.4	94.3	52.8	3.3	0	207	477.3	0	0	0	0	0	0
balance-sheet.row.total-debt	678.32	145.1	205.3	167.3	222.7	167.3	306	367	487	490	0	0	0	0	0	0
balance-sheet.row.net-debt	610.18	141.7	193.1	145.6	216.9	124.6	237.9	335.3	462	243.8	-85.4	-346.8	-446.8	-33.6	-149.8	-9.9

现金流量表

在 Hainan Shuangcheng Pharmaceuticals Co., Ltd. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 -3.836 的转变。该公司最近通过发行 0 扩大了股本，与上一年相比出现了0.480 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 19.57. 公司的投资活动产生了现金使用净额，按报告货币计算达到-85071692.340. 与上一年相比， -3.578 发生了变化. 在同一时期，公司记录了 57.54, 0 和 -12，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将-11.13 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 68.07，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009
cash-flows.row.net-income	-63.99	-8.5	-40.8	-79.9	9	-92.1	1.3	-388.4	52.7	58.9	66.8	68	70.4	64.2	32.1
cash-flows.row.depreciation-and-amortization	40.38	57.5	54.3	57.1	59	56.1	43.5	29.2	20.7	17.4	12.6	7.6	5.7	5	3.7
cash-flows.row.deferred-income-tax	-3.82	-0.4	0.4	1.2	1.5	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	1.42	6.9	7.2	-1.2	-1.5	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	-10.62	-4.5	14.9	-12.2	26.1	60.4	-37.2	112	-29.2	-12.3	-10.9	5.7	-10.3	-12.1	5
cash-flows.row.account-receivables	4.99	-13.8	5.4	39.8	8.2	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-12.45	-9.9	-4.8	-4.3	39.6	31.3	-89.6	-6.2	14.2	-22.4	-7.2	-11.3	-1.8	-0.6	-2.4
cash-flows.row.account-payables	0	19.6	13.8	-48.9	-23.2	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	-3.17	-0.4	0.4	1.2	1.5	29.1	52.3	118.2	-43.4	10.2	-3.7	16.9	-8.5	-11.5	7.4
cash-flows.row.other-non-cash-items	45.94	-25.8	-12.5	24.5	-27.6	22.5	-30.1	285.8	2.1	-13	-12	-1.1	0.3	-1.8	3.5
cash-flows.row.net-cash-provided-by-operating-activities	7.88	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-50.56	-33	-31.6	-51.6	-51.5	-22.4	-70.2	-183	-289.7	-115.9	-65.1	-57.9	-107.1	-9.5	-23.3
cash-flows.row.acquisitions-net	14.27	27	21.7	53.6	74	0	0.7	2	0.1	0	65.1	57.9	0	-1	0
cash-flows.row.purchases-of-investments	-193.85	-471	-256.2	-637.2	-507.6	-775.3	-315.3	-8	-835.3	-1850	-2070.6	-441	0	-160	0
cash-flows.row.sales-maturities-of-investments	263.71	391.9	299.2	615.3	599.4	915.9	302	6.4	729	1704	2024	280.9	0	161.4	0
cash-flows.row.other-investing-activites	13.08	0	0	-51.6	-51.5	7.6	12.7	2.2	-0.7	-15.1	-65.1	-57.9	0	0	0.1
cash-flows.row.net-cash-used-for-investing-activites	16.89	-85.1	33	-71.5	62.8	125.9	-69.9	-180.4	-396.5	-277.1	-111.7	-218	-107.1	-9.2	-23.2
cash-flows.row.debt-repayment	-92.11	-12	-55.3	-1.8	-139	-106	-475	-196.4	-70	0	0	0	0	0	-16
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-7.78	-11.1	-9.1	-9.8	-10.1	-16.7	-7.5	-25.2	-43	-36	-44	0	-75.1	0	-16.3
cash-flows.row.other-financing-activites	35.64	68.1	23.8	57	-5.3	-11.4	586.6	209.8	553.9	0	0	550	0	93.7	16
cash-flows.row.net-cash-used-provided-by-financing-activities	-13.02	44.9	-40.6	45.4	-154.3	-134	104.1	-11.7	440.9	-36	-44	550	-75.1	93.7	-16.3
cash-flows.row.effect-of-forex-changes-on-cash	0.01	0.1	-0.1	-0.3	0	-2.7	-3.4	1.1	0.7	-0.3	0	0.1	-0.1	0	0
cash-flows.row.net-change-in-cash	11.76	-14.8	15.8	-36.9	-24.9	36	8.2	-152.4	91.4	-262.4	-99.2	412.4	-116.2	139.9	4.8
cash-flows.row.cash-at-end-of-period	68.14	6.8	21.6	5.8	42.7	67.6	31.6	23.4	175.8	84.4	346.8	446	33.6	149.8	9.9
cash-flows.row.cash-at-beginning-of-period	56.38	21.6	5.8	42.7	67.6	31.6	23.4	175.8	84.4	346.8	446	33.6	149.8	9.9	5.2
cash-flows.row.operating-cash-flow	7.88	25.2	23.6	-10.5	66.6	46.8	-22.5	38.6	46.2	51	56.4	80.2	66.1	55.3	44.3
cash-flows.row.capital-expenditure	-50.56	-33	-31.6	-51.6	-51.5	-22.4	-70.2	-183	-289.7	-115.9	-65.1	-57.9	-107.1	-9.5	-23.3
cash-flows.row.free-cash-flow	-42.68	-7.8	-8.1	-62.1	15.1	24.5	-92.7	-144.3	-243.4	-64.9	-8.6	22.3	-41.1	45.8	20.9

利润表行

Hainan Shuangcheng Pharmaceuticals Co., Ltd. 的收入与上期相比变化了 -0.141%。据报告, 002693.SZ 的毛利润为 161.07。该公司的营业费用为 183.42，与上年相比变化了 -14.998%. 折旧和摊销费用为 57.54，与上一会计期间相比变化了 -0.085%. 营业费用报告为 183.42，显示-14.998% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长-1.988%. 营业收入为 -73.15，与上年相比变化了1.988%. 净利润的变化率为 4.972%。去年的净收入为-50.74.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010
income-statement-row.row.total-revenue	197.21	235.9	274.8	320.3	269.4	346.6	337.2	246.8	145.1	231	161.2	149.6	129.7	133.5	112.9	88.2
income-statement-row.row.cost-of-revenue	68.14	74.9	88.3	81.4	60.2	95.1	120.9	91.5	69.9	102.1	55.9	52.8	37.1	33.7	28.4	28.9
income-statement-row.row.gross-profit	129.06	161.1	186.5	238.9	209.3	251.5	216.4	155.3	75.2	128.8	105.3	96.8	92.5	99.8	84.5	59.2
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	8.41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	20.73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	80.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	0.19	0.2	63.2	69	69.7	41.5	-3.1	2.2	4.2	5.1	-0.4	3.5	6.6	2.5	0.6	0.9
income-statement-row.row.operating-expenses	164.04	183.4	215.8	282.7	264.6	272.7	283.8	182.9	179.3	73.4	54.2	42	26.5	23.6	15.1	20.8
income-statement-row.row.cost-and-expenses	232.18	258.3	304.1	364.1	324.8	367.8	404.7	274.4	249.2	175.5	110.1	94.7	63.7	57.3	43.4	49.7
income-statement-row.row.interest-income	0.04	0	0.1	0.1	0.1	0.6	0.3	0.3	0.2	0.9	5	7.9	6.2	1.6	0.3	0
income-statement-row.row.interest-expense	9.04	9.6	11.2	9	10	9.8	17.5	16.6	15.3	16.1	4.6	0	0	0	0	0.3
income-statement-row.row.selling-and-marketing-expenses	80.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-58.06	-50.6	15.6	2	-25.6	24.3	-25.9	30.7	-281	6.8	18	23.8	13.9	3.8	2.7	-2.6
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	0.19	0.2	63.2	69	69.7	41.5	-3.1	2.2	4.2	5.1	-0.4	3.5	6.6	2.5	0.6	0.9
income-statement-row.row.total-operating-expenses	-58.06	-50.6	15.6	2	-25.6	24.3	-25.9	30.7	-281	6.8	18	23.8	13.9	3.8	2.7	-2.6
income-statement-row.row.interest-expense	9.04	9.6	11.2	9	10	9.8	17.5	16.6	15.3	16.1	4.6	0	0	0	0	0.3
income-statement-row.row.depreciation-and-amortization	32.98	52.7	57.5	54.3	57.1	59	56.1	43.5	29.2	20.7	17.4	12.6	7.6	5.7	5	3.7
income-statement-row.row.ebitda-caps	-31.85	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-87.45	-73.2	-24.5	-42.3	-53.2	-13.7	-90.2	0.9	-389.1	57.4	69.7	75.2	73.3	77.9	71.5	38.7
income-statement-row.row.income-before-tax	-87.26	-73	-8.9	-40.4	-78.8	10.5	-93.4	3.1	-385.1	62.3	69.1	78.6	80	80	72.2	35.9
income-statement-row.row.income-tax-expense	-12.63	-1	-0.4	0.4	1.2	1.5	-1.2	1.8	3.3	9.6	10.2	11.9	12	9.6	7.9	3.8
income-statement-row.row.net-income	-63.99	-50.7	-8.5	-40.8	-79.9	9	-69.5	6.3	-388.4	52.7	58.9	66.8	68	70.4	64.2	32.1